K-CAB and Fexuclue, new P-CAB drugs, expand globally

K-CAB receives product approval in Chile and it has entered 35 countries through technology exports or finished product exports

Fexuclue has been introduced to 24 countries within a year of its launch and aims to reach 1 trillion in sales

HK inno.N’s K-CAB (Left) and Daewoong Pharmaceutical’s Fexuclue (Right).

New P-CAB class drugs, K-CAB (tegoprazan) and Fexuclue (fexuprazan), for treating gastroesophageal reflux disease are competing for global entries.

 

HK inno.N’s K-CAB has entered 35 countries globally through technology exports or finished product exports.

 

Within a year of its launch, Daewoong Pharmaceutical’s Fexuclue has been introduced to 24 countries, including Korea.

 

Both companies are aiming to reach 1 trillion in sales.

 

K-CAB has expanded to 35 countries globally, and the company “Aims to achieve 1 trillion won in global sales” HK inno.N announced on the 20th that K-CAB has recently received product approval from the Agencia Nacional de Medicamentos (ANAMED) in Chile.

 

In Peru, the drug will be marketed under the name ‘Ki-CAB.’ Ki-CAB received approval for four indications: ▲Treatment of erosive gastroesophageal reflux disease, ▲Treatment of non-erosive gastroesophageal reflux disease, ▲Treatment of gastric ulcer, and ▲Antibiotic combination therapy for the eradication of Helicobacter pylori in patients with peptic ulcer or chronic atrophic gastritis.

 

K-CAB has launched or is awaiting launch after receiving product approval in nine countries, including Korea.

 

In Asia, K-CAB is sold in China, Mongolia, the Philippines, Indonesia, and Singapore.

 

In Latin America, it is available in Mexico and Peru.

 

Furthermore, K-CAB will be available in Chile as it has obtained product approval.

 

The company seems particularly focused on expanding into the Latin American market.

 

In 2018, HK inno.N signed a contract for finished product exports with Laboratorios Carnot and 17 Latin American countries.

 

Furthermore, the company launched products in Mexico and Peru in May and October.

 

In December 2022, the company exported K-CAB technology to Brazil, the largest pharmaceutical market in Latin America.

 

HK inno.N said they expect drug approvals in various Latin American countries this year.

 

The company’s strategy is to expedite entering the Latin American pharmaceutical market, valued at 72 trillion won.

 

Besides Latin America, K-CAB has entered 35 countries around the world, including the United States and China, through technology exports or finished product exports.

 

HK inno.N aims to accelerate its global entry and enter 100 countries by 2028.

 

Through this, the company aims to achieve its goal of 1 trillion sales.

 

Dal Won Kwak, CEO of HK inno.N, said, “As we await approval in various Latina American countries this year, K-CAB’s global entry is expected to accelerate.”

K-CAB has expanded to 35 countries and Fexuclue has entered 24 countries within a year of its launch.

Within a year of its launch, Fexuclue has entered 24 countries, with the “Goal of reaching 100 countries by 2027” Fexuclue is also rapidly expanding its global presence.

 

Just one year after its launch, the drug has already reached 24 countries outside of Korea.

 

Fexuclue was officially launched in the Philippines in August last year, marking its first overseas launch.

 

Furthermore, Fexuclue is also set to launch in Mexico, Ecuador, and Chile, where it has received product approvals.

 

Daewoong has applied for product approvals in 13 countries including China, Saudi Arabia, Morocco, Malaysia, Singapore, Costa Rica, and Panama.

 

Last December, Daewoong agreed on exports with India’s number one pharmaceutical company, Sun Pharma.

 

The countries that agreed on Fexuclue export deals now include India, the United Arab Emirates, Bahrain, Kuwait, Oman, and Qatar, bringing the total to six countries.

 

Daewoong is planning to apply for product approval in 30 counties by next year.

 

Also, the company aims to expand its entry into 100 counties world-wide by 2027.

 

The global sales target is set at 1 trillion won, which is the same as K-CAB’s.

 

“Fexuclue achieved noticeable accomplishments, including entering the world’s fourth antiulcer drug market, India,” Daewoong Pharmaceutical Vice President Park Sung-soo said.

 

“We aim to expedite Fexuclue approval in all countries and launch in Mexico this year.

 

Our objective is to expand to 100 countries by 2027.”